Peto, R; Collins, R; Sackett, D; Darbyshire, J; Babiker, A; Buyse, M; ... Doll, R; + view all Peto, R; Collins, R; Sackett, D; Darbyshire, J; Babiker, A; Buyse, M; Stewart, H; Baum, M; Goldhirsch, A; Bonadonna, G; Valagussa, P; Rutqvist, L; Elbourne, D; Davies, C; Dalesio, O; Parmar, M; Hill, C; Clarke, M; Gray, R; Doll, R; - view fewer (1997) The trials of Dr Bernard Fisher: A European perspective on an American episode. CONTROL CLIN TRIALS , 18 (1) 1 - 13.
Full text not available from this repository.
Writing from across the Atlantic, we have tried to imagine what we, as 20 European biostatisticians and clinical trialists, might have said if any of us had been in Dr. Fisher's place in 1994. He was being interrogated in Washington at a special hearing of a Congressional subcommittee, having been called to answer charges of ''failure of scientific integrity'' of which he was, in any normal usage of the English language, quite innocent. Despite this, however, he and his statistical colleague had already, at the insistence of the then director of the U.S. National Cancer Institute (NCI), been summarily removed by their university from the large and important breast cancer trial organization they had built up over many years, and recruitment of additional patients had been prevented. Moreover, further regulatory constraints on all U.S.-funded cancer trials were being drawn up Which, however well-intentioned, may well do more harm than good to patients. The background to these events is, unfortunately of general relevance to American medical research.
|Title:||The trials of Dr Bernard Fisher: A European perspective on an American episode|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health Care > Infection and Population Health|
UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > MRC Clinical Trials Unit at UCL
Archive Staff Only: edit this record